| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1052490854 |
| P356 | DOI | 10.2165/00003495-200767180-00007 |
| P698 | PubMed publication ID | 18062721 |
| P2093 | author name string | Torbjörn Tomson | |
| Dina Battino | |||
| P2860 | cites work | Common antiepileptic drugs in pregnancy in women with epilepsy | Q24246634 |
| The longer term outcome of children born to mothers with epilepsy | Q24671544 | ||
| Congenital Abnormalities and Anticonvulsant Drugs | Q24683057 | ||
| Spectrum of neural-tube defects in 34 infants prenatally exposed to antiepileptic drugs | Q28319658 | ||
| The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort | Q28319660 | ||
| Prenatal diagnosis of spina bifida aperta after first‐trimester valproate exposure | Q28342767 | ||
| Additional educational needs in children born to mothers with epilepsy | Q28345141 | ||
| Long-term neuropsychological consequences of maternal epilepsy and anticonvulsant treatment during pregnancy for school-age children and adolescents | Q28372866 | ||
| Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy | Q28379440 | ||
| Monitoring of zonisamide in human breast milk and maternal plasma by solid-phase extraction HPLC method | Q30745335 | ||
| Foetal malformations and seizure control: 52 months data of the Australian Pregnancy Registry. | Q31046235 | ||
| Valproic acid embryopathy: report of two siblings with further expansion of the phenotypic abnormalities and a review of the literature | Q32063425 | ||
| Safety of the newer antiepileptic drug oxcarbazepine during pregnancy | Q33217593 | ||
| Change of seizure frequency in pregnant epileptic women | Q33619066 | ||
| Neural-tube defects | Q33772419 | ||
| Folic acid antagonists during pregnancy and the risk of birth defects. | Q33926560 | ||
| Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. | Q33976947 | ||
| Epilepsy and pregnancy | Q71377534 | ||
| Changes in primidone/phenobarbitone ratio during pregnancy and the puerperium | Q71388524 | ||
| Folate levels and neural tube defects. Implications for prevention | Q71516278 | ||
| [Uncontrolled retrospective study of 75 pregnancies in women treated for epilepsy] | Q71586661 | ||
| Assessing risk to benefit ratio in antiepileptic drug therapy | Q34001648 | ||
| Is carbamazepine teratogenic? A prospective controlled study of 210 pregnancies | Q34084799 | ||
| Birth weight in offspring of women with epilepsy | Q34161995 | ||
| Pregnancy in women with epilepsy. | Q34165034 | ||
| Gabapentin exposure in human pregnancy: results from the Gabapentin Pregnancy Registry | Q34203694 | ||
| Anti-epileptic agents during pregnancy. A prospective study on the course of pregnancy, malformations and child development | Q34259052 | ||
| Effect of folic acid supplementation on congenital malformations due to anticonvulsive drugs | Q34262735 | ||
| Anticonvulsants during pregnancy and lactation. Transplacental, maternal and neonatal pharmacokinetics | Q34270748 | ||
| Passage of S(+) and R(-) gamma-vinyl-GABA across the human isolated perfused placenta | Q34403607 | ||
| Antiepileptic drugs: indications other than epilepsy. | Q34549201 | ||
| In utero antiepileptic drug exposure: fetal death and malformations | Q34555052 | ||
| Antiepileptic drug disposition during pregnancy | Q34555578 | ||
| Ethosuximide in epileptic women during pregnancy and lactation period. Placental transfer, serum concentrations in nursed infants and clinical status | Q34621665 | ||
| Serum folate concentrations during pregnancy in women with epilepsy: relation to antiepileptic drug concentrations, number of seizures, and fetal outcome. | Q34994741 | ||
| Long term health and neurodevelopment in children exposed to antiepileptic drugs before birth | Q35439268 | ||
| Fetal phenytoin exposure, hypoplastic nails, and jitteriness | Q35626324 | ||
| Malformation rates in children of women with untreated epilepsy: a meta-analysis | Q35645910 | ||
| Vigabatrin: placental transfer in vivo and excretion into breast milk of the enantiomers | Q35802976 | ||
| Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register | Q36142531 | ||
| The significance of folic acid for epilepsy patients | Q36213106 | ||
| Safety of antiepileptic drugs during pregnancy | Q36235506 | ||
| Best practice guidelines for the management of women with epilepsy | Q36319420 | ||
| Pharmacokinetics and therapeutic drug monitoring of newer antiepileptic drugs during pregnancy and the puerperium | Q36747433 | ||
| Antiepileptic drug exposure and major congenital malformations: the role of pregnancy registries | Q36998327 | ||
| Population based, prospective study of the care of women with epilepsy in pregnancy | Q37356427 | ||
| Epilepsy and pregnancy--a review of 98 pregnancies | Q37786706 | ||
| Fetal growth, major malformations, and minor anomalies in infants born to women receiving valproic acid | Q39289571 | ||
| Minor anomalies in offspring of epileptic mothers | Q39296948 | ||
| Teratogenicity of anticonvulsant drugs. II: A prospective study | Q39346774 | ||
| Anticonvulsants and parental epilepsy in the development of birth defects | Q39367479 | ||
| The contribution of maternal epilepsy and its treatment to the etiology of oral clefts: a population based case-control study | Q39383827 | ||
| Psychomotor development and minor anomalies in children exposed to antiepileptic drugs in utero: a prospective population-based study. | Q39530338 | ||
| A rational antiepileptic drug therapy of epileptic women in child bearing age. | Q39570719 | ||
| Lactic acidosis following convulsions | Q44406243 | ||
| Teratogenicity of antiepileptic drugs: analysis of possible risk factors | Q44536887 | ||
| The Australian registry of anti-epileptic drugs in pregnancy: experience after 30 months | Q44568739 | ||
| Epilepsy and pregnancy: a study of 153 pregnancies in 59 patients | Q44669789 | ||
| Epilepsy and pregnancy: lamotrigine as main drug used | Q44678739 | ||
| Normal intelligence in children with prenatal exposure to carbamazepine | Q44725516 | ||
| The impact of pregnancy and childbirth on the metabolism of lamotrigine. | Q44743465 | ||
| Serum folic acid levels in epileptic mothers and their relationship to congenital malformations | Q44813696 | ||
| Oxcarbazepine in pregnancy: clinical experience in Argentina | Q44880512 | ||
| Gestation-induced changes in lamotrigine pharmacokinetics: a monotherapy study | Q45013907 | ||
| Epilepsy, pregnancy, and major birth anomalies: an Italian prospective, controlled study | Q45252192 | ||
| Seizure control and treatment in pregnancy: observations from the EURAP epilepsy pregnancy registry | Q46342696 | ||
| Pregnancy with epilepsy--a retrospective analysis | Q46360784 | ||
| Congenital malformations due to anticonvulsive drugs | Q46390577 | ||
| Neuropsychological effects of exposure to anticonvulsant medication in utero | Q46395855 | ||
| Antiepileptic drugs and teratogenicity in Nigerians | Q46424076 | ||
| Levetiracetam concentrations in serum and in breast milk at birth and during lactation | Q46460413 | ||
| Antiepileptic drug use of women with epilepsy and congenital malformations in offspring | Q46546783 | ||
| Children exposed to valproate in utero--population based evaluation of risks and confounding factors for long-term neurocognitive development | Q46609023 | ||
| Individual changes in lamotrigine plasma concentrations during pregnancy. | Q46638387 | ||
| Outcomes of pregnancy associated with antiepileptic drugs | Q46662637 | ||
| Pharmacokinetics of gabapentin during delivery, in the neonatal period, and lactation: does a fetal accumulation occur during pregnancy? | Q46725879 | ||
| Gender aspects of pharmacokinetics of new and old AEDs: pregnancy and breast-feeding | Q46888276 | ||
| Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and the puerperium | Q46984904 | ||
| Pregnancies of women with epilepsy: a population-based study in Iceland | Q47634154 | ||
| Congenital malformations in infants of mothers with diabetes and epilepsy in Western Australia, 1980-1982. | Q47699262 | ||
| Multi-institutional study on the teratogenicity and fetal toxicity of antiepileptic drugs: a report of a collaborative study group in Japan | Q47880779 | ||
| Carbamazepine: Placental Transport, Tissue Concentrations in Foetus and Newborn, and Level in Milk | Q48269272 | ||
| Specific cognitive dysfunction in children with epileptic mothers | Q49012441 | ||
| Homocysteine metabolism in pregnancies complicated by neural-tube defects | Q49274779 | ||
| The effects of valproate exposure in utero on behavior and the need for educational support in school-aged children. | Q51911328 | ||
| The psychological development of children of epileptic parents. I. Study design and comparative findings. | Q52024122 | ||
| The teratogenicity of hydantoins and barbiturates in humans, with considerations on the etiology of malformations and cerebral disturbances in the children of epileptic parents | Q52102505 | ||
| The psychological development of children of epileptic parents. II. The differential impact of intrauterine exposure to anticonvulsant drugs and further influential factors. | Q52214956 | ||
| The effects of prenatal exposure to phenytoin and other anticonvulsants on intellectual function at 4 to 8 years of age | Q52230107 | ||
| Antiepileptic drugs and teratogenesis in two consecutive cohorts: changes in prescription policy paralleled by changes in pattern of malformations. | Q52231982 | ||
| Antiepileptic medication in pregnancy: late effects on the children's central nervous system development. | Q52238514 | ||
| Carbamazepine levels in breast milk. | Q52432839 | ||
| Teratogenic effect of anticonvulsant drugs. | Q52711878 | ||
| Plasma concentrations of carbamazepine and carbamazepine 10,11-epoxide during pregnancy and after delivery. | Q53812686 | ||
| [Letter: Teratogenic hazards in antiepileptic therapy] | Q54115341 | ||
| Neonatal effects of maternal treatment with the anticonvulsant drug diphenylhydantoin. | Q54182086 | ||
| Seizure disorder in mothers of children with orofacial clefts: a case-control study. | Q54339342 | ||
| Congenital malformations and anticonvulsant drugs. | Q54619230 | ||
| Risk factors for the increased seizure frequency during pregnancy and puerperium. | Q54651170 | ||
| Are anticonvulsants teratogenic? | Q54764449 | ||
| Congenital malformation among offspring of epileptic women. | Q55061341 | ||
| Carbamazepine and its metabolites in human perfused placenta and in maternal and cord blood. | Q55064154 | ||
| Birth outcomes in women exposed to anticonvulsant drugs | Q57301012 | ||
| Epilepsy and Pregnancy: A Report from the Oxford Record Linkage Study | Q57386258 | ||
| Trimestral changes of seizure frequency in pregnant epileptic women | Q71637697 | ||
| Congenital abnormalities, cleft lip and cleft palate in particular, in children of epileptic mothers | Q71810261 | ||
| Preliminary report on teratogenic effects of zonisamide in the offspring of treated women with epilepsy | Q71864319 | ||
| Epilepsy and pregnancy: a prospective study of seizure control in relation to free and total plasma concentrations of carbamazepine and phenytoin | Q72252243 | ||
| Disposition of carbamazepine and phenytoin in pregnancy | Q72252246 | ||
| Pregnancy, epilepsy, management and outcome: a 10-year perspective | Q72373564 | ||
| Anticonvulsant drug therapy in human pregnancy: Effects on serum concentrations of vitamin D metabolites in maternal and cord blood | Q72395734 | ||
| The effect of pregnancy on the epilepsies: a study of 37 pregnancies | Q72607251 | ||
| Pharmacokinetics of oxcarbazepine and carbamazepine in human placenta | Q73155698 | ||
| Antiepileptic drug regimens and major congenital abnormalities in the offspring | Q73162968 | ||
| Teratogenic effects of antiepileptic drugs: use of an International Database on Malformations and Drug Exposure (MADRE) | Q73187776 | ||
| Anticonvulsants and congenital malformations | Q73371219 | ||
| Intelligence and physical features of children of women with epilepsy | Q73417777 | ||
| Prenatal exposure to valproic acid during pregnancy and limb deficiencies: a case-control study | Q73519728 | ||
| Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation | Q73855666 | ||
| Epilepsy and pregnancy | Q73913638 | ||
| Pregnancy and epilepsy: a retrospective study of 151 pregnancies | Q74412462 | ||
| Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy | Q74526092 | ||
| Outcome of pregnancies in epileptic women: a study in Saudi Arabia | Q74635775 | ||
| On the transfer of barbiturates to the human foetus and their accumulation in some of its vital organs | Q74659945 | ||
| Epilepsy and pregnancy: an obstetric perspective | Q76380559 | ||
| ARE ANTI-EPILEPTIC DRUGS HARMFUL DURING PREGNANCY? | Q76844900 | ||
| [Zonisamide:its placental transport, biological half-life in the newborn, and transport to mother's milk--a study of a case of an infant born of a mother who had been treated with zonisamide alone during pregnancy] | Q77292469 | ||
| Placental transfer of phenobarbitone in epileptic women, and elimination in newborns | Q78394168 | ||
| Valproate effects on kinetics of lamotrigine in pregnancy and treatment with oral contraceptives | Q79215719 | ||
| The frequency of neonatal morbidity after exposure to antiepileptic drugs in utero: a retrospective population-based study | Q79830201 | ||
| Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation | Q80024568 | ||
| The AED (antiepileptic drug) pregnancy registry: a 6-year experience | Q80098015 | ||
| EURAP: an international registry of antiepileptic drugs and pregnancy | Q80917985 | ||
| Community-based, prospective, controlled study of obstetric and neonatal outcome of 179 pregnancies in women with epilepsy | Q82283060 | ||
| Pregnancy and perinatal outcome in epileptic women: a population-based study | Q82623866 | ||
| Obstetric outcome in women with epilepsy | Q93588599 | ||
| Carbamazepine protein binding and disposition in pregnancy | Q93625130 | ||
| [Epilepsy and pregnancy. Seizure incidence and serum concentration of antiepileptic agents] | Q93666118 | ||
| Epilepsy and cleft lip and palate | Q93692170 | ||
| Are anticonvulsants teratogenic? | Q93708453 | ||
| Teratogenic effect of anticonvulsants | Q93729703 | ||
| Congenital malformations among infants born to epileptic women | Q93731523 | ||
| Teratogenic efect of anticonvulsants | Q93731981 | ||
| Placental transfer and neonatal elimination of diphenylhydantoin | Q93819621 | ||
| Drug Kinetics in Pregnancy | Q39636007 | ||
| Fetal heart rate during a maternal grand mal epileptic seizure | Q39650236 | ||
| Drug metabolism in pregnancy, infancy and childhood | Q39671443 | ||
| Maternal epilepsy, antiepileptic drugs and birth defects | Q39687510 | ||
| Family studies in fetal phenytoin exposure | Q39713856 | ||
| Epilepsy and pregnancy: a review of 26 patients | Q39714709 | ||
| Studies on long-lasting consequences of prenatal exposure to anticonvulsant drugs | Q40397293 | ||
| Navigating toward fetal and maternal health: the challenge of treating epilepsy in pregnancy. | Q40478338 | ||
| Current Management of Epilepsy and Pregnancy: Fetal Outcome, Congenital Malformations, and Developmental Delay | Q40603184 | ||
| Pharmacokinetics of anticonvulsants in pregnancy: alterations in plasma protein binding | Q41237446 | ||
| Epilepsy Among Parents of Children with Facial Clefts | Q41445113 | ||
| Microlissencephaly with cardiac, spinal and urogenital defects | Q41923563 | ||
| The teratogenicity of anticonvulsant drugs | Q41923758 | ||
| Findings in children exposed in utero to phenytoin and carbamazepine monotherapy: independent effects of epilepsy and medications | Q41927333 | ||
| Epilepsy, antiepileptic drugs, and malformations in children of women with epilepsy: a French prospective cohort study | Q41930405 | ||
| Maternal seizure disorder, outcome of pregnancy, and neurologic abnormalities in the children | Q41935146 | ||
| Teratogenic and pharmacokinetic studies of primidone during pregnancy and in the offspring of epileptic women | Q41935354 | ||
| Maternal epilepsy and abnormalities of the fetus and newborn | Q41938113 | ||
| Improved pregnancy outcome in epileptic women in the last decade: relationship to maternal anticonvulsant therapy | Q42161971 | ||
| Maternal epilepsy and birth defects: a case-control study in the Italian Multicentric Registry of Birth Defects (IPIMC). | Q42226379 | ||
| Do anticonvulsants have a teratogenic effect? | Q42232913 | ||
| Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy | Q42275048 | ||
| Two siblings with fetal hydantoin syndrome | Q42540859 | ||
| Spina bifida and in-utero exposure to valproate | Q42591453 | ||
| Maternal valproic acid and congenital neural tube defects | Q42591925 | ||
| In-utero exposure to valproate and neural tube defects. | Q42685178 | ||
| Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register | Q43405933 | ||
| Neural tube defects in relation to use of folic acid antagonists during pregnancy | Q43625422 | ||
| Antiepileptics and the development of congenital anomalies | Q43626441 | ||
| Repeated neural tube defects and valproate monotherapy suggest a pharmacogenetic abnormality | Q43650811 | ||
| Lamotrigine and the risk of malformations in pregnancy | Q43669569 | ||
| Intelligence of children of epileptic mothers | Q43680106 | ||
| Pattern of malformations in the children of women treated with carbamazepine during pregnancy | Q43779596 | ||
| Increased rate of major malformations in offspring exposed to valproate during pregnancy | Q43905735 | ||
| Transplacental passage of oxcarbazepine and its metabolites in vivo | Q43906050 | ||
| Pharmacokinetics of zonisamide in perinatal period | Q43916058 | ||
| Factors influencing the risk of abnormal pregnancy outcome in epileptic women: a multi-centre prospective study | Q43986196 | ||
| Psychomotor development in preschool children exposed to antiepileptic drugs in utero. | Q44025166 | ||
| Epilepsy in pregnancy: developmental outcome of offspring at 12 months. | Q44062918 | ||
| Lamotrigine clearance during pregnancy | Q44075693 | ||
| Valproate embryopathy in three sets of siblings: further proof of hereditary susceptibility | Q44115123 | ||
| Topiramate kinetics during delivery, lactation, and in the neonate: preliminary observations | Q44169560 | ||
| Antiepileptic therapy and teratogenicity in Turkey | Q44208313 | ||
| Outcome of pregnancy in women attending an outpatient epilepsy clinic: adverse features associated with higher doses of sodium valproate | Q44237611 | ||
| Anticonvulsant drugs in monotherapy. Effect on the fetus | Q44252535 | ||
| Major malformations in offspring of women with epilepsy | Q44324825 | ||
| Transplacental passage of lamotrigine in a human placental perfusion system in vitro and in maternal and cord blood in vivo | Q44334635 | ||
| Maternal plasma folate and vitamin B12 are independent risk factors for neural tube defects | Q57677677 | ||
| Malformations in Offspring of Women with Epilepsy: A Prospective Study | Q59222991 | ||
| Oxcarbazepine concentrations during pregnancy: A retrospective study in patients with epilepsy | Q61849473 | ||
| Congenital malformations due to antiepileptic drugs | Q61922624 | ||
| Teratogenic Risks of Antiepileptic Drugs in Respect to the Type of Epilepsy | Q66980735 | ||
| Plasma anticonvulsant concentrations during pregnancy | Q67010508 | ||
| The course of epilepsy during pregnancy: a study of 78 cases | Q67238839 | ||
| [Pregnancy and epilepsy] | Q67335093 | ||
| Congenital malformations and seizure disorders in the offspring of parents with epilepsy | Q67417404 | ||
| Epilepsy, anticonvulsants and pregnancy | Q67598112 | ||
| Maternal drug histories and congenital abnormalities | Q67709605 | ||
| Risks to the offspring of women treated with hydantoin anticonvulsants, with emphasis on the fetal hydantoin syndrome | Q67791578 | ||
| Evaluation of anticonvulsant drugs during pregnancy in a population-based Hungarian study | Q68106052 | ||
| Malformation in infants of mothers with epilepsy receiving antiepileptic drugs | Q68108165 | ||
| Major and minor birth malformations and antiepileptic drugs | Q68108174 | ||
| Primidone and Phenobarbital during Lactation Period in Epileptic Women: Total and Free Drug Serum Levels in the Nursed Infants and Their Effects on Neonatal Behavior | Q68410857 | ||
| Pharmacokinetics of oxcarbazepine and 10-hydroxy-carbazepine in the newborn child of an oxcarbazepine-treated mother | Q68449510 | ||
| Antiepileptic drug intake during pregnancy and malformed offspring | Q68686749 | ||
| Epilepsy and pregnancy: a study of 188 pregnancies in 92 patients | Q68702453 | ||
| Anti-epileptics and congenital malformations | Q68922414 | ||
| [The frequency of crises in epileptic women during pregnancy: a prospective study] | Q69090837 | ||
| Is disordered folate metabolism the basis for the genetic predisposition to neural tube defects? | Q69123620 | ||
| Genetics and fetal hydantoin syndrome | Q69178735 | ||
| Incidence of seizures during pregnancy, labor and puerperium in epileptic women: a prospective study | Q69182408 | ||
| Serum phenytoin during pregnancy, labor and puerperium | Q69257080 | ||
| Facial and oral form in sibs of children with cleft lip with or without cleft palate | Q69367839 | ||
| Anticonvulsant drugs and malformations is there a drug specificity? | Q69587303 | ||
| [Newborn infants from epileptic mothers: malformation and auxonologic risk] | Q69604097 | ||
| The Teratological Effects of Anticonvulsants and the Effects on Pregnancy and Birth | Q69623751 | ||
| Pregnancy and epilepsy | Q69681145 | ||
| Anticonvulsants, folate levels, and pregnancy outcome: a prospective study | Q69777145 | ||
| Epilepsy in pregnancy | Q69795109 | ||
| Concentration of valproate during pregnancy, in the newborn and in breast milk | Q69977161 | ||
| Letter: Anticonvulsants and congenital abnormalities | Q70017846 | ||
| Congenital heart defects in live-born children of epileptic parents | Q70083177 | ||
| Plasma antiepileptic drug concentrations during pregnancy | Q70118695 | ||
| Outcome of pregnancies complicated by epilepsy in Tasmania 1981-1988 | Q70258696 | ||
| [Children of epileptic mothers (author's transl)] | Q70276726 | ||
| [The teratogenic risks of anti-epileptic treatment] | Q70454716 | ||
| Valproic acid in breast milk: how much is really there? | Q70508673 | ||
| Epilepsy and pregnancy | Q70512842 | ||
| Teratogenicity of anticonvulsant drugs. IV: The association of clefting and epilepsy | Q70696915 | ||
| The teratological problem of antiepileptic drugs | Q70726902 | ||
| Teratogenic effects of anticonvulsants | Q70832407 | ||
| The clearance of anticonvulsant drugs in pregnancy | Q71120024 | ||
| Placental transfer and pharmacokinetics of primidone and its metabolites phenobarbital, PEMA and hydroxyphenobarbital in neonates and infants of epileptic mothers | Q71265317 | ||
| P433 | issue | 18 | |
| P304 | page(s) | 2727-2746 | |
| P577 | publication date | 2007-01-01 | |
| P1433 | published in | Drugs | Q3040094 |
| P1476 | title | Management of epilepsy during pregnancy. | |
| P478 | volume | 67 |
| Q60667230 | Advances in Epidemiological Methods and Utilisation of Large Databases: A Methodological Review of Observational Studies on Central Nervous System Drug Use in Pregnancy and Central Nervous System Outcomes in Children |
| Q26858860 | Advantages and problems with pregnancy registries: observations and surprises throughout the life of the International Lamotrigine Pregnancy Registry |
| Q42926141 | Comparative pharmacodynamic and pharmacokinetic analysis of two anticonvulsant halo derivatives of 2,2,3,3-tetramethylcyclopropanecarboxamide, an amide of a cyclic analog of valproic acid. |
| Q64985073 | Design and pharmacological activity of glycinamide and N-methoxy amide derivatives of analogs and constitutional isomers of valproic acid. |
| Q37821471 | Disease registries and outcomes research in children: focus on lysosomal storage disorders |
| Q51512151 | Effect of pregnancy on topiramate pharmacokinetics in rabbits. |
| Q36969393 | Epilepsy drugs and effects on fetal development: Potential mechanisms |
| Q50891749 | Evaluation of apoptotic cell death on liver and kidney tissues following administration of levetiracetam during prenatal period. |
| Q51166297 | Impact of pregnancy on zonisamide pharmacokinetics in rabbits. |
| Q37396442 | Management of newly diagnosed epilepsy: a practical guide to monotherapy |
| Q35185771 | Oxcarbazepine-loaded polymeric nanoparticles: development and permeability studies across in vitro models of the blood-brain barrier and human placental trophoblast. |
| Q34942400 | Pharmacotherapeutics of epilepsy: use of lamotrigine and expectations for lamotrigine extended release |
| Q36012665 | Prenatal antiepileptic exposure associates with neonatal DNA methylation differences |
| Q35871433 | Reduced Adult Hippocampal Neurogenesis and Cognitive Impairments following Prenatal Treatment of the Antiepileptic Drug Valproic Acid |
| Q38085336 | Safety of disease-modifying drugs for multiple sclerosis in pregnancy: current challenges and future considerations for effective pharmacovigilance. |
| Q36425094 | The course and outcome of pregnancy and neonatal situation in epileptic women |
| Q43079101 | The safety or risk of antihistamine use in pregnancy: reassuring data are helpful but not sufficient |
| Q83298965 | [Fears, knowledge, and need of counseling for women with epilepsy. Results of an outpatient study] |
Search more.